Clinical characteristics and immunomodulatory therapy of vaccinated and COVID-19 recovered patients
| Vaccinated (n=264) | COVID-19 recovered (n=26) | |
| Diagnosis, n (%) inflammatory arthritis | 152 (58) | 16(58) |
| Rheumatoid arthritis | 96 (37) | 11 (42) |
| Juvenile arthritis | 4 (2) | |
| Psoriatic arthritis | 30 (12) | 1 (4) |
| Spondyloarthropathy | 21 (8) | 3 (12) |
| Sarcoidosis | 1 (0.4) | 1 (4) |
| Connective tissue diseases | 87 (34) | 9 (35) |
| Systemic sclerosis | 50 (19) | 5 (19) |
| Systemic lupus erythematosus | 25 (10) | 2 (0.8) |
| Myositis | 9 (3) | 1 (4) |
| Sjogren | 2 (0.7) | |
| MCTD** | 1 (0.4) | 1 (4) |
| Vasculitis | 19 (7) | 1 (4) |
| Granulomatosis with polyangiitis | 4 (2) | |
| Eosinophilic granulomatosis with polyangiitis | 3 (1) | |
| Takayasu vasculitis | 7 (3) | 1 (4) |
| Behcet’s disease | 4 (2) | |
| Polyarteritis nodosa | 1 (0.4) | |
| Others†† | 6 (2) | |
| Therapy, n (%) | ||
| None | 22 (8.3) | 3 (11) |
| csDMARDs | 160 (60.6) | 15 (58) |
| Methotrexate | 78 (29.5) | 5 (19) |
| Mycophenolate mofetil | 26 (9.8) | 7 (27) |
| Salazopyrine | 7 (0.3) | 1 (4) |
| Hydroxychloroquine | 43 (16) | 5 (19) |
| Leflunomide | 13 (5) | 0 |
| Azathioprine | 14 (5) | 1 (4) |
| Purimethol | 2 (0.7) | 0 |
| Cyclosporine | 1 (0.3) | 0 |
| Colchicine | 6 (0.2) | 0 |
| Nintedanib | 3 (0.1) | 1 (4) |
| Biological/targeted DMARDs | 178 (67.4) | 19 (73) |
| B-cell depleting (anti-CD-20) | 48 (18.2) | 5 (19) |
| Belimumab | 11 (4.2) | 3 (11) |
| Anti-TNF§ | 63 (23.9) | 8 (31) |
| Anti-interleukins¶ | 40 (15.2) | 2 (8) |
| Abatacept | 8 (3) | 1 (4) |
| Anti-JAK** agents | 9 (3.4) | 0 |
| Combined therapy‡‡ | 95 (36) | 11 (42) |
| Corticosteroids | 92 (34.8) | 13 (50) |
*Mixed connective tissue disease.
†IGG4-related disease, idiopathic recurrent pericarditis, familial mediterranean fever, polymyalgia rheumatica, adult Still’s disease.
‡csDMARDs+b/tsDMARDs; conventional synthetic disease-modifying antirheumatic drugs+biological/targeted synthetic DMARDs.
§Anti-TNF (infliximab, adalimumab, golimumab, certolizumab, etanercept).
¶Anti-interleukins (tocilizumab, sarilumab, secukinumab, ixekizumab, ustekinumab, risankizumab, mepolizumab, anakinra).
**Anti-JAK agents (tofacitinib, baricitinib, upadacitinib).
DMARDs, disease-modifying antirheumatic drugs; IGG4, immunoglobulin G4; JAK, janus kinase; MCTD, mixed connective tissue disease.